By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

PTC Therapeutics, Inc. 

100 Corporate Court

South Plainfield  New Jersey  07080-2449  U.S.A.
Phone: 908-222-7000 Fax: 908-222-7231


SEARCH JOBS



Segment
Drug Discovery





Company News
PTC Therapeutics (PTCT) Release: European Commission (EC) Ratifies Positive CHMP Opinion For The Renewal Of Translarna Marketing Authorization For The Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy 1/10/2017 11:07:31 AM
PTC Therapeutics (PTCT) Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna And Advance Its Innovative Pipeline 1/9/2017 10:48:44 AM
PTC Therapeutics (PTCT) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 1/6/2017 8:35:12 AM
PTC Therapeutics (PTCT) Release: RG7916 Granted Orphan Drug Designation In The U.S. For The Treatment Of Spinal Muscular Atrophy 1/6/2017 8:26:18 AM
PTC Therapeutics (PTCT) Announces Initiation Of FIREFISH Study In Infant (Type I) SMA Patients 1/5/2017 10:42:21 AM
PTC Therapeutics (PTCT) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 12/19/2016 9:47:44 AM
PTC Therapeutics (PTCT) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/21/2016 6:59:46 AM
PTC Therapeutics (PTCT) Rockets as DMD Drug Wins Extended European Approval 11/11/2016 6:23:28 AM
PTC Therapeutics (PTCT) Reports Third Quarter 2016 Financial Results And Provides Corporate Update 11/3/2016 9:44:12 AM
PTC Therapeutics (PTCT) Release: Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916 10/21/2016 6:49:03 AM
12345678910...
//-->